Drugs / CS01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07461181 | Dec 2024 → Dec 2026 expected | — | Ruijin Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07461181 ↗ |
| Action | Activate | “CS01 is a novel agonistic anti-OX40 IgG monoclonal antibody” NCT07461181 ↗ |
| Modality | Monoclonal antibody | “CS01 is a novel agonistic anti-OX40 IgG monoclonal antibody” NCT07461181 ↗ |
| Route | Intravenous | “All patients will receive CS01 injection via intravenous infusion” NCT07461181 ↗ |